**Supplementary Figure:**

**Enrollment and disposition of study participants, Tenofovir in Pregnancy (TIP) Study**

Terminated pregnancy after randomization (n=1)

Excluded (n=41)

* Already on HAART: 19
* Terminated pregnancy: 10
* Presented after 28 weeks gestation: 8
* Declined: 4

Screened for the study (n=76)

Randomized (n=35)

Assigned to TDF/3TC arm (n=18)

Assigned to 3TC arm (n=17)

Delivered by January 2016 (n=16)

Delivered by January 2016 (n=15)

**Supplementary Table:**

**Multivariable analysis of factors associated with HBV viral load at delivery among HIV/HBV co-infected Pregnant Women, Tenofovir in Pregnancy (TIP) Study**

|  |  |
| --- | --- |
|  | **Undetectable HBV viral load at delivery** |
|  | **Unadjusted** | **Adjusted\*** |
|  | **RR (95% CI)\*\*** | **p-value** | **RR (95% CI)\*\*** | **p-value** |
|  |  |  |  |  |
| TDF/3TC study arm | 0.68 (0.38 – 1.21) | 0.19 | 0.78 (0.51 – 1.18) | 0.24 |
|  |  |  |  |  |
| Weeks on study arm  | 0.98 (0.92 – 1.06) | 0.65 | - |  |
|  |  |  |  |  |
| Baseline HBV viral load >200,000 IU/ml | 0.12 (0.02 – 0.76) | 0.02 | 0.12 (0.02 – 0.78) | 0.03 |
|  |  |  |  |  |
| Age (per 1 year increase) | 1.02 (0.97 – 1.08) | 0.36 | - |  |
|  |  |  |  |  |
| BMI (per 1 kg/m2 increase) | 0.99 (0.89 – 1.09) | 0.78 | - |  |
|  |  |  |  |  |
| Baseline ALT (per 10 mU/ml increase) | 0.99 (0.87 – 1.12) | 0.85 | - |  |
|  |  |  |  |  |
| Baseline hemoglobin(per 1 g/dl increase) | 1.00 (0.76 – 1.31) | 0.99 | - |  |
|  |  |  |  |  |
| Baseline CD4+ T cell count(per 100 count/mm3 increase) | 1.11 (1.01 – 1.23) | 0.04 | - |  |
|  |  |  |  |  |
| Baseline log10 HIV viral load(per 1 log10 copies/ml increase) | 1.09 (0.79 – 1.52) | 0.59 | - |  |
|  |  |  |  |  |
| Positive baseline HBeAg | 0.14 (0.02 – 0.87) | 0.04 | - |  |

\* Multivariable model including study arm and baseline HBV viral load

\*\* Relative risk estimated using Poisson regression with robust error variances